UP-421

N/A

Report date: 2025/03/21 11:28:28

Base Information

Drug NameUP-421
Drug Alias NameHIP-pancreatic islet cell therapyUP421UP-421
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionHuman leukocyte antigen modulatorsPancreatic beta cell replacements
TargetsHuman leukocyte antigen
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSana Biotechnology Inc
China Registration ClassN/A

Develop Information

Active CompaniesUppsala University HospitalSana Biotechnology Inc
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A